期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀类药物治疗糖尿病伴代谢综合征的作用机制 被引量：5

下载PDF
导出
摘要 他汀类药物可用于糖尿病伴有代谢综合征的治疗,其作用机制主要是减轻胰岛素抵抗及胰岛β细胞的损伤,改善高血压、血脂障碍和高血粘度,防治心脑血管疾病、减少心脑动脉事件发生和保护肾功能、减少蛋白尿等。
作者 陈育 黄贵心
机构地区 广东医学院附属医院内分泌科
出处 《广东医学院学报》 2007年第2期215-217,共3页 Journal of Guangdong Medical College
关键词 他汀类 糖尿病 代谢综合征X 综述文献
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献22

  • 1ONG H T.The statin studies:from targetinghypercholesterolaemia to targeting thehigh-risk patient[J].QJM,2005,98(8):599-614.
  • 2JACOBSON T A.Statin safety:lessons from new drug applications for marketed statins[J].Am J Cardiol,2006,97(8A):44C-51C.
  • 3UMEJI K,UMEMOTO S,ITOH S,et al.Comparative effects of pitavastatin and probucol on oxidative stress,Cu/Zn superoxide dismutase,PPAR-gamma,and aortic stiffness inhypercholesterolemia[J].Am J Physiol Heart Circ Physiol,2006,291(5):H2522-2532.
  • 4KINLAY S.Potential vascular benefits of statins[J].Am J Med,2005,118(Suppl 12A):62-67.
  • 5SJOHOLM A,BERGGREN PO,COONEY R V.gamma-tocopherol partially protects insulin-secreting cells against functional inhibition by nitric oxide[J].Biochem Biophys Res Commun,2000,277 (2):334-340.
  • 6WAGNER A H,SCHWABE O,HECKER M.Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ[J].Br J Pharmacol,2002,136(1):143-149.
  • 7BELL R M,YELLON D M.Atorvastatin,administered at the onset of reperfusion,and independent of lipid lowering,protects the myocardium by up-regulating a pro-survival pathway[J].J Am Coll Cardiol,2003,41(3):508-515.
  • 8LAM H C,CHU C H,WEI M C,et al.The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia[J].Exp Biol Med (Maywood),2006,231 (6):1010-1015.
  • 9DEEDWANIA PC,HUNNINGHAKE D B,BAYS H E,et al.Effects of rosuvastatin,atorvastatin,simvastatin,and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome[J].Am J Cardiol,2005,95(3):360-366.
  • 10FAN P,ZHANG B,KUROKI S,et al.Pitavastatin,a potenthydroxymethylglutaryl coenzyme a reductase inhibitor,increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells[J].Circ J,2004,68(11):1061-1066.

同被引文献42

  • 1宋贺,胡慧华,王东华,赖泽文.他汀类药物研究进展:临床证据[J].中国老年学杂志,2007,27(11):1118-1119. 被引量：4
  • 2Dallinga-Thie GM, Berk-Planken II, Bootsma AH, et al. Atorvastatin Decreases Apolipoprotein C-III in Apoli- poprotein B - Containing Lipoprotein and HDL in Type 2 Diabetes[J]. Diabetes Care,2004,27(6) :1358-1364.
  • 3Mukherjee S, Mukhopadhyay P, Pandit K, et al. Atorvastatin Improves Arterial Stiffness in Normotensive Normolipidaemic Persons with Type 2 Diabetes [ J ]. J Indian Med Assoc,2008,106( 11) :716-719.
  • 4Colhoun HM, Betteridge D J, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS) : multicentre randomised placebocontrolled trial[ J ]. Lancet,2004,364 ( 21 ) :685-696.
  • 5Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary.heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction[J]. N Engl J Med ,1998,339(4) : 229-234,.
  • 6Gaspardone A, Arca M. Atorvastatin: its clinical role in cerebrovascular prevention [ J ]. Drugs ,2007,67 Suppl 1 : 55-62.
  • 7Kappelle P,Zwang L, Huisman MV, et al. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by' triglycerides and cholesteryl ester transfer protein [ J ] . Expert Opin, 2009 , 13 (7) :743-751:.
  • 8Dallinga-Thie GM, van Tol A, Hattori H , et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes [ J ]. Diabetologia, 2006,49 ( 7 ) : 1505-1511.
  • 9Diabetes atorvastin lipid intervention (DALI)study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia[ J]. Diabetes Care,2001,24(8) :1335-1341.
  • 10Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S)and the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS)[J]. AmJ Cardiol,2004,93:136-141

引证文献5

二级引证文献14

广东医学院学报
2007年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部